Rapport Therapeutics, Inc. — Form 8-K
Filed November 4, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Rapport reported positive Phase 2 results for RAP-219 in bipolar mania (N=253): met primary endpoint with 3.1-point placebo-adjusted improvement in YMRS score (p=0.045) and pre-specified secondary endpoint (p=0.024); well tolerated with no serious adverse events. Company raised ~$410.7M gross proceeds in October 2026 (public offering of common stock and convertible notes due 2032) plus ~$10M via ATM in November 2026, bringing total cash to ~$815.4M as of November 3, 2026, with runway through end of 2029. Two Phase 3 trials in bipolar mania expected to initiate in 2H 2027 following FDA End-of-Phase 2 meeting (planned Q1 2027).
Why this rating
Proof-of-concept in second major indication materially strengthens lead asset pipeline; $421M capital raise (149% of market cap) extends runway and validates market confidence. Significant but not transformational—Phase 3 success not guaranteed; clinical-stage company remains pre-revenue.
Price action (we called it positive)
at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.